Ionis Pharmaceuticals, Inc.
IONS
$32.96
$0.060.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.48% | 30.57% | 29.00% | 34.84% | 34.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.48% | 30.57% | 29.00% | 34.84% | 34.10% |
| Cost of Revenue | 0.44% | -3.96% | -0.90% | 5.09% | 7.26% |
| Gross Profit | -71.42% | 65.33% | 64.28% | 51.06% | 53.40% |
| SG&A Expenses | 25.80% | 9.95% | 37.18% | 35.91% | 41.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.25% | -1.47% | 5.11% | 9.87% | 12.41% |
| Operating Income | -42.36% | 36.94% | 26.83% | 20.94% | 18.64% |
| Income Before Tax | -37.76% | 5.25% | -25.25% | -18.54% | -29.45% |
| Income Tax Expenses | -119.10% | -91.12% | -52.05% | -4.58% | 175.37% |
| Earnings from Continuing Operations | -23.92% | 12.37% | -18.35% | -16.99% | -35.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.92% | 12.37% | -18.35% | -16.99% | -35.80% |
| EBIT | -42.36% | 36.94% | 26.83% | 20.94% | 18.64% |
| EBITDA | -44.33% | 37.69% | 27.28% | 21.03% | 18.44% |
| EPS Basic | -18.79% | 14.66% | -16.65% | -15.45% | -34.60% |
| Normalized Basic EPS | -40.45% | 39.68% | 27.98% | 27.37% | 25.04% |
| EPS Diluted | -18.79% | 14.66% | -16.65% | -15.45% | -34.60% |
| Normalized Diluted EPS | -40.45% | 39.68% | 27.98% | 27.37% | 25.04% |
| Average Basic Shares Outstanding | 4.35% | 2.27% | 1.58% | 1.31% | 1.02% |
| Average Diluted Shares Outstanding | 4.35% | 2.27% | 1.58% | 1.31% | 1.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
